Bisacyloxypropylcysteine conjugates and the use thereof

Details Bisacyloxypropylcysteine conjugates and the use thereof Bisacyloxypropylcysteine conjugates and the use thereof

2008-01-08

2008-01-08

Gupta, Anish (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S018700, C514S019300, C514S186000, C530S331000, C530S359000, C562S426000, C562S556000

Reexamination Certificate

active

07316996

ABSTRACT:
The invention provides lipopeptide conjugates in which a cysteine that is double-substituted by a fatty acid is bonded by means of the carboxyl group to a highly soluble, physiologically compatible and non-immunogenic, polymeric conjugate group. The conjugates exhibit an excellent macrophage stimulant action and do not require addition solutizing. They can be used in a wide range of applications, in particular for stimulating macrophages, for stimulating antibody synthesis, for combating infection, as an immunostimulant, in particular in relation to tumors, for preventing and treating septicaemic shock, for would healing and as an adjuvant for vaccines.

REFERENCES:
patent: 5580563 (1996-12-01), Tam
patent: 6573242 (2003-06-01), Muehlradt
patent: 0 510 356 (1992-10-01), None
patent: 0 604 945 (1994-07-01), None
patent: 0 604 957 (1994-07-01), None
patent: 0 638 588 (1995-02-01), None
patent: WO 00/42175 (2000-07-01), None
Muller MR, Pfannes SDC, Ayoub M, Hoffmann P, Bessler WG, Mittenbuhler K, Immunostimulation by the synthetic lipopeptide P3CSK4: TLR4-independent activation of the ERK1/2 signal transduction pathway in macrophages, Immunology, 2001, 103: 49-60.
Esche UVD, Ayoub M, Pgannes SDC, Muller MR, Huber M, Wiesmuller KH, Loop T, Humar M, Fischbach KF, Strunkelnberg M, Hoffmann P, Bessler WG, Mittenbuhler K, Immunostimulation by bacterial components: I. Activation of macrophages and enhancement of genetic immunization by the lipopeptide P3CSK4, Int J of Immunopharm, 2000, 22: 1093-1102.
Raghow R, THe role of extracellular matrix in postinflammatory wound healing and fibrosis, FASEB J, 1994, 8: 823-831.
Annane D, Sebille V, Troche G, Raphael JC, Gajdos P, Bellissant E, A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin, JAMA, 2000, 283(8): 1038-1045.
Parrillo JE, Pathogenetic Mechanisms of Septic Shock, NEJM, 1993, 328(20): 1471-1478.
Harris JM, Martin NE, Modi M, Pegylation, Drug Delivery Systems, Clin Pharmacokinet, 2001, 40(7): 539-551.
Veronese FM, Peptide and protein PEGylation: a review of problems and solutions, Biomaterials, 2001, 22: 405-417.
Roberts MJ, Bentley MD, Harris JM, Chemistry for peptide and protein PEGylation, Advanced Drug Delivery Reviews, 2002, 54: 459-476.
Kim WJH, Cellular SIgnaling in Tissue Regeneration, Yonsei Medical Journal, 2000, 41(6): 692-703.
Sepsis and Septic Shock from the Merck Index.
XP-002257581 Rharbaou i et al. “The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant” Eur. J. Immunol, 2002, 32; 2857-2865.
XP-002237893, Polyethylene Glycol; pp. 392-393 & 398.
XP-002257580 Takeuchi et al.“Cutting Edge: Preferentially the R-Stereoisomer of the Mycoplasmal Lipopetide Macrophage-Activating Lipopeptide -2 Activates Immune Cell Through a Toll-Like Receptor 2-and MyD88-Dependent Signaling Pathway” Cutting Edge; pp 1-4, 2000.
Metzger et al. “Synthesis of N-Fmoc protected derivatives of S-(2,3 dihydroxypropyl)-cysteine and their application in peptide synthesis” Int. J. Peptide Protein Res. 38 1991; pp. 545-554.
Hoffmann et al. “Stimulation of Human and Murine Adherent Cells by Bacterial Lipoprotein and Synthetic Lipopeptide Analogues” Immunbiol., vol. 177, pp. 158-170 1988.
Metzger et al. “Synthesis of novel immunologically active tripalmitoyl-S-glycerlcysteinyl lipopeptides as useful intermediates for immunogen preparations” Int. J. Peptide Protein Res. 37, 1991, pp. 46-57.
Muhlradt et al. “Purification and Partial Biochemical Characterization of a Mycoplasma fermentans-Derived Substance That Activates Macrophages To Release Nitric Oxide, Tumor Necrosis Factor, and Interleukin-6” Infection and Immunity, Sep. 1994 pp. 3801-3887, vol. 62 No. 9.

Affiliated with

Also associated with

Rating

Bisacyloxypropylcysteine conjugates and the use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bisacyloxypropylcysteine conjugates and the use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bisacyloxypropylcysteine conjugates and the use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2813588